Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 12Cisplatin 12Leucovorin 9Paclitaxel 8Radiotherapy 6Oxaliplatin 5Capecitabine 5Irinotecan 4Gastrectomy 3Epirubicin 3Trastuzumab 2Taxes 2Surgical Procedures, Operative 2Platinum 2Neoadjuvant Therapy 2Docetaxel 2uridine triacetate 1sargramostim 1pertuzumab 1carfilzomib 1Watchful Waiting 1Vorinostat 1Sorafenib 1Ramucirumab 1Radiosurgery 1Preoperative Exercise 1Polymerase Chain Reaction 1Ondansetron 1Lithium 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Stomach Neoplasms × AMG 337 × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡